Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study

References

• Abutaleb, A., & Sherman, K. E. (2018). A changing paradigm: Management and treatment of the HCV/HIV-co-infected patient. Hepatology International. doi: 10.1007/s12072-018-9896-4
   Web of Science ®Google Scholar
• Collins, L. F., Chan, A., Zheng, J., Chow, S. C., Wilder, J. M., Muir, A. J., & Naggie, S. (2018). Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infectious Diseases, 5, 1. doi: 10.1093/ofid/ofx264
   Web of Science ®Google Scholar
• Flisiak, R., Zarebska-Michaluk, D., Janczewska, E., Staniaszek, A., Gietka, A., Mazur, W., … Pawlowska, M. (2018). Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study. Journal of Viral Hepatitis, 25(6), 661–669. doi: 10.1111/jvh.12861
   PubMed Web of Science ®Google Scholar
• Gayam, V., Hossain, M. R., Khalid, M., Chakaraborty, S., Mukhtar, O., Dahal, S., … Mohanty, S. (2018). Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C/human immunodeficiency virus coinfection in a community care setting. Gut and Liver. doi: 10.5009/gnl18004
   PubMed Web of Science ®Google Scholar
• Graham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T., & Koziel, M. J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Journal of Biochemistry and Molecular Biology, 33(4), 562–569. doi: 10.1086/321909
   Google Scholar
• Grzeszczuk, A., Wandalowicz, A. D., Jaroszewicz, J., & Flisiak, R. (2015). Prevalence and risk factors of HCV/HIV Co-infection and HCV genotype distribution in North-Eastern Poland. Hepatitis Monthly, 15(7), e27740. doi: 10.5812/hepatmon.27740v2
   PubMed Web of Science ®Google Scholar
• Hawkins, C., Grant, J., Ammerman, L. R., Palella, F., McLaughlin, M., Green, R., … Stosor, V. (2016). High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: A real-world perspective. Journal of Antimicrobial Chemotherapy, 71(9), 2642–2645. doi: 10.1093/jac/dkw203
   PubMed Web of Science ®Google Scholar
• Henry, Z., & Gonzales Zamora, J. A. (2018). Evolution of pretreatment assessment and direct acting antiviral regimens in accordance with upgrading guidelines: A retrospective study in HIV/HCV coinfected patients. Medical Sciences (Basel), 6, 4. doi: 10.3390/medsci6040081
   Google Scholar
• Horban, A., Cholewińska, G., Wiercińska-Drapało, A., Knysz, B., Inglot, M., Szymczak, A, … Jabłonowska, E. (2017). Zasady Opieki nad Osobami Zakażonymi HIV, Polish AIDS Society, & Warszawa-Wrocław, pp. 1–488.
   Google Scholar
• Ingiliz, P., Christensen, S., Kimhofer, T., Hueppe, D., Lutz, T., Schewe, K., … Mauss, S. (2016). Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: Results from the German hepatitis C Cohort (GECCO-01). Journal of Biochemistry and Molecular Biology, 63(10), 1320–1324. doi: 10.1093/cid/ciw567
   Google Scholar
• Jablonowska, E., & Malolepsza, E. (2009). Profile of patients with newly diagnosed HIV in the Łódź region in Poland from 1996 to 2005. Archives of Medical Science, 5(4), 577–582.
   Web of Science ®Google Scholar
• Leszczyszyn-Pynka, M., Ciejak, P., Maciejewska, K., Witak-Jedra, M., Karasinska-Cieslak, M., Karpinska, E., … Parczewski, M. (2018). Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland. Archives of Medical Science, 14(3), 554–559. doi: 10.5114/aoms.2016.58744
   PubMed Web of Science ®Google Scholar
• Lo Re, V. 3rd, Kallan, M. J., Tate, J. P., Localio, A. R., Lim, J. K., Goetz, M. B., … Justice, A. C. (2014). Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Annals of Internal Medicine, 160(6), 369–379. doi: 10.7326/M13-1829
   PubMed Web of Science ®Google Scholar
• Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., … Investigators, I. O. N. (2015). Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 705–713. doi: 10.1056/NEJMoa1501315
   PubMed Web of Science ®Google Scholar
• Parczewski, M., Siwak, E., Leszczyszyn-Pynka, M., Cielniak, I., Burkacka, E., Pulik, P., … Horban, A. (2017). Meeting the WHO 90% target: Antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. Journal of the International AIDS Society, 20(1), 21847. doi: 10.7448/IAS.20.1.21847
   PubMedGoogle Scholar
• Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., … Vickerman, P. (2016). Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis. The Lancet Infectious Diseases, 16(7), 797–808. doi: 10.1016/S1473-3099(15)00485-5
   PubMed Web of Science ®Google Scholar
• Pol, S., & Parlati, L. (2018). Treatment of hepatitis C: The use of the new pangenotypic direct-acting antivirals in “special populations”. Liver International, 38(Suppl 1), 28–33. doi: 10.1111/liv.13626
   PubMed Web of Science ®Google Scholar
• Rice, D. P., Ordoveza, M. A., Palmer, A. M., Wu, G. Y., & Chirch, L. M. (2018). Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients. AIDS Care, 30(12), 1507–1511. doi: 10.1080/09540121.2018.1499857
   PubMed Web of Science ®Google Scholar
• Rosinska, M., Janiec, J., & Niedzwiedzka-Stadnik, M. (2013). Increase of new HIV diagnoses among men who have sex with men in Poland, 2000 to 2011. Euro Surveillance, 18(48), 20642–20646. doi: 10.2807/1560-7917.ES2013.18.48.20642
   PubMedGoogle Scholar
• Rowan, S. E., Rogers, M., Bayer, J., Smith, L., Gardner, E. M., Johnson, S., & Langness, J. (2016). Treatment of hepatitis C virus in HIV-coinfected individuals in real-world clinical settings: Results from 2 large HIV care clinics. Journal of Biochemistry and Molecular Biology, 63(7), 994–995. doi: 10.1093/cid/ciw447
   Google Scholar
• Saeed, S., Strumpf, E. C., Walmsley, S. L., Rollet-Kurhajec, K., Pick, N., Martel-Laferriere, V., … Wong, D. (2016). How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real World? Journal of Biochemistry and Molecular Biology, 62(7), 919–926. doi: 10.1093/cid/civ1222
   Google Scholar
• Sikavi, C., Najarian, L., & Saab, S. (2018). Similar sustained virologic response in real-world and clinical trial studies of hepatitis C/human immunodeficiency virus coinfection. Digestive Diseases and Sciences, 63(11), 2829–2839. doi: 10.1007/s10620-018-5215-0
   PubMed Web of Science ®Google Scholar
• Sulkowski, M. S., Eron, J. J., Wyles, D., Trinh, R., Lalezari, J., Wang, C., … Podsadecki, T. (2015). Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: A randomized trial. The Journal of the American Medical Association, 313(12), 1223–1231. doi: 10.1001/jama.2015.1328
   PubMed Web of Science ®Google Scholar
• Tapper, E. B., Bacon, B. R., Curry, M. P., Dieterich, D. T., Flamm, S. L., Guest, L. E., … Afdhal, N. H. (2016). Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology, 64(6), 1893–1899. doi: 10.1002/hep.28782
   PubMed Web of Science ®Google Scholar
• Thein, H. H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology, 48(2), 418–431. doi: 10.1002/hep.22375
   PubMed Web of Science ®Google Scholar